((自动化翻译由路透提供，请见免责声明 ))
12月2日 - ** Cytokinetics 股价盘前下跌2.3%至50.67美元
** CYTK称美国食品和药物管理局已同意审查其心脏病药物aficamten的上市申请
** 美国食品和药物管理局指定的行动日期为 2025 年 9 月 26 日 - CYTK
** 至少有两位分析师表示，由于aficamten的标准审查期与投资者对优先审查的预期不同，CYTK的股价今天可能会走弱，而优先审查可能会导致该药提前上市。
** 公司正在寻求批准该药物用于治疗阻塞性肥厚型心肌病，这种病的心脏肌肉变得僵硬，可能导致心脏骤停。
** Truist分析师说，标准审查使CYTK有机会提交作为一线治疗药物的数据，这有助于使它与竞争对手百时美施贵宝 的Camzyos区别开来。
** Piper Sandler称，FDA的认可增强了人们对该药成功的信心，并坚信该药的标签不会像Camzyos那么严格。
** 截至上次收盘，CYTK 的年累计跌幅约为 48
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.